Aastrom Biosciences Inc. (ASTM) announced Friday that the first patients were treated in a phase 2b clinical trial of ixCELL-DCM. The study is evaluating the safety and efficacy of ixmyelocel-T compared to placebo in patients with advanced heart failure due to ischemic dilated cardiomyopathy (ischemic DCM). Aastrom has received U.S. orphan drug designation for the use of ixmyelocel-T in patients with DCM.
ASTM closed Friday's trading at $0.71, down 0.01%.
Bioniche Life Sciences Inc. (BNC.TO), which experienced increased trading activity of its shares on the Toronto Stock Exchange on Friday, said that there has been no material change in its business. The company added that one of its institutional shareholders - the Fonds de solidarité FTQ - has sold their entire holding.
BNC.TO closed Friday's trading at C$0.27, up 14.89% on a volume of 8.33 million shares.
Shares of BioTime Inc. (BTX) rose more than 6% on Friday following the signing of a worldwide license agreement with the University of California, Los Angeles, or UCLA, to develop therapy for the treatment of stroke. The licensed technology, developed in UCLA's Department of Neurology, uses one of BioTime's HyStem hydrogels to deliver locally released growth factors to improve recovery from stroke.
Shares of Novadaq Technologies Inc. (NVDQ) (NDQ.TO) touched a new high of $12.98 on Friday before closing at $12.73 after the company announced promising interim results from a clinical trial evaluating its FDA-cleared PINPOINT Endoscopic Fluorescence Imaging System in laparoscopic colorectal surgery.
In the trial dubbed, PILLAR II, the PINPOINT Endoscopic Fluorescence Imaging System enabled surgeons to assess the quality of tissue perfusion at the anastomotic site, which cannot be done using traditional laparoscopes.
Omeros Corp. (OMER) is scheduled to present additional data from recent phase 2 and phase 3 clinical trials evaluating its ophthalmology product, OMS302, for use during intraocular lens replacement, including cataract surgery and refractive lens exchange on April 21 at the Annual American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Symposium and Congress.
The company expects to submit a New Drug Application to the FDA for OMS302 this quarter and a Marketing Authorization Application to the European Medicines Agency in mid-2013.
OMER closed Friday's trading at $3.90, down 1.02%.
by RTT Staff Writer
For comments and feedback: email@example.com